Tempus AI and Boehringer Ingelheim Collaborate to Advance Cancer Research and Development

Strategic Insights -

Tempus AI, Inc. and Boehringer Ingelheim have entered a new strategic collaboration to accelerate the discovery and development of new treatments for hard-to-treat cancers. This multi-year agreement builds on the companies' existing partnership, leveraging data and artificial intelligence to drive therapeutic research and development. The collaboration aims to explore data from patient cohorts to guide biomarker development and patient stratification, develop drug combination hypotheses, and support novel target discovery efforts.

Key Takeaways:

  • The collaboration between Tempus AI and Boehringer Ingelheim aims to advance the discovery and development of new treatments for hard-to-treat cancers by leveraging data and artificial intelligence.
  • The partnership will explore data from patient cohorts to guide biomarker development and patient stratification, develop drug combination hypotheses, and support novel target discovery efforts.
  • Boehringer Ingelheim will have access to Tempus' de-identified database containing molecular, clinical, and imaging data, as well as its analytical platform, Lens.
  • Mark Paul Petronczki, Head of Oncology Research at Boehringer Ingelheim, stated that the integration of internal and real-world data will deepen the understanding of cancer biology and accelerate drug discovery and development efforts.
  • Jan Nygaard Jensen, Head of Computational Innovation at Boehringer Ingelheim, emphasized the importance of harnessing advanced AI methodologies to drive innovation and enhance the precision and efficiency of pharmaceutical research.
  • Ryan Fukushima, Chief Operating Officer at Tempus, expressed excitement about expanding the company's work with the Boehringer team and deploying multiple solutions to their growing oncology pipeline.
  • The collaboration aims to bring novel treatments to patients faster by applying the power of data and AI to cancer research and development.

Statistics:

  • 2025: The fiscal year in which Tempus' Quarterly Report on Form 10-Q was filed with the Securities and Exchange Commission (SEC).
  • 68%: The percentage of hard-to-treat cancers that Boehringer Ingelheim is committed to changing through the discovery and development of new breakthrough treatments.
  • 10-15%: The expected acceleration of drug discovery and development efforts through the use of real-world data and AI methodologies.

Sources:

  • BusinessWire: "Tempus AI and Boehringer Ingelheim Collaborate to Advance Cancer Research and Development"
  • Tempus Website: "About Tempus"
  • Temporary and SEC filings: "Risk Factors in the section titled 'Risk Factors'" in Tempus' Quarterly Report on Form 10-Q for the fiscal quarter ended February 24, 2025.